The options for people who want to quit smoking increased by one this week with the introduction of a new treatment approved by Health Canada. Varenicline tartrate (Champix) is a new class of medications specifically designed to compete with nicotine’s affect on the brain. What are the indications for its use? What is its efficacy? What have clinical trials shown? What are the long-term success rates?
- Dr. Andrew Pipe, Medical Director of the University of Ottawa Heart Institute Prevention and Rehabilitation Centre, and Professor at the University of Ottawa and President of the Commonwealth Games Canada.
[display_podcast]